Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
437 Leser
Artikel bewerten:
(1)

Vodori, Inc.: Vodori Announces Expansion in Europe to Meet the Growing Demand for Modern Life Science Software Worldwide

UK commercial partnership will drive expanded sales and service of Vodori's software platform across the European market

CHICAGO and LONDON, June 16, 2022 /PRNewswire/ -- Vodori, creator of cloud-based software that streamlines and automates how life science companies deliver critical content to key audiences, today announced its expansion into Europe in response to market demand through its long-term partnership with 3SIX Health. The newly-appointed UK team of highly experienced life science and health-tech professionals now provide dedicated resources for Vodori's growing European base of pharmaceutical, biotechnology, medical device, and diagnostics customers.

Vodori Announces Expansion in Europe to Meet the Growing Demand for Modern Life Science Software Worldwide

Ross Grey, Co-Founder and Director of 3SIX Health, serves as Vodori's Commercial Director of UK/EU and brings over 15 years of experience within the pharmaceutical and life science industry, holding a number of director level commercial roles. Grey comments "Driving the Vodori European expansion enables us to increase market access to this innovative MLR system that will fundamentally increase collaboration and accelerate growth for life science companies."

Flynn Pharma is already a UK based customer of Vodori. James Leighton-Scott, Chief Medical Officer explains "Review and certification of promotional materials within a pharmaceutical company is a critical process. I have used several such systems throughout my career and Vodori's Pepper Flow has been the best I have encountered. Great news that Vodori is expanding operations in Europe; the team's extensive industry experience will no doubt make the operation very successful."

"We see a genuine opportunity for Vodori to expand into local markets and provide innovative software solutions to customers whose options were previously limited," says Dr. Joe DiCapite, Co-Founder and Director of 3SIX Health and Vodori's Director of Strategy of UK/EU.

"I am delighted to appoint a team of experienced individuals who will propel our momentum throughout Europe," says Scott Rovegno, Vodori Founder and CEO. "This commercial partnership will provide immense value through the team's rich backgrounds, extensive MLR review experience, and wealth of commercial expertise in the European market."

About Vodori

Vodori is transforming lives by empowering life science companies to bring vital drugs, vaccines, medical devices, and diagnostic solutions to market faster. Vodori's Pepper Cloud Product Suite streamlines and automates how life science companies get critical content to key audiences including patients, healthcare providers, and key opinion leaders. It is one connected platform that modernizes content review, sales and MSL enablement, and delivers timely analytics to optimize essential processes. For more information, visit vodori.com.

About 3SIX Health

3SIX Health is a UK based healthcare company with one vision: to simplify healthcare. 3SIX was launched through the belief that navigating healthcare can be unnecessarily complex and a strong desire to reduce this complexity. Using experience working in science, business, pharmaceuticals and disruptive technology, 3SIX provides bespoke solutions to exceed customer needs. For more information, visit 3SIXhealth.co.uk.

Contact
Annalise Ludtke
Vodori, Inc.
269.808.0012
annalise.ludtke@vodori.com

Photo - https://mma.prnewswire.com/media/1840706/vodori_UK_EU_expansion.jpg

© 2022 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.